Latest Sarcoma Stories
INDIANAPOLIS, May 27, 2011 /PRNewswire/ -- In the press release, "Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas," issued May 19, 2011, by Eli Lilly and Company (NYSE: LLY), the following sentence has been amended to: The best overall responses were as follows: one partial response in the Ewing sarcoma tier (n=1); and no partial responses, but stable disease of 41 percent (n=9) in leiomyosarcoma; 35 percent (n=6) in synovial sarcoma; 28 percent (n=5) in Ewing family of...
Researchers from Mount Sinai School of Medicine have discovered a protein signaling pathway that becomes hyperactivated in human sarcoma cells, suggesting that medications to inhibit this pathway may be effective in the treatment of human sarcomas.
INDIANAPOLIS, May 19, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced data from its Phase II study with cixutumumab in five subtypes of sarcoma, a cancer that develops from connective tissues in the body.
SAN DIEGO, May 12, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that the Company will highlight clinical development plans for its Phase 3-ready pegylated arginine deiminase, ADI-PEG 20, during a symposium held on Tuesday, May 24, at 1:30 p.m.
Arsenic is usually thought of as a poison.
Chief of Orthopedic Oncology in the Departments of Orthopedic Surgery and Director of the Sarcoma Divisions of the Cancer Centers, Mount Sinai Medical Center and Hackensack University Medical Center, James C.
Researchers have identified an important signaling pathway that, when blocked, significantly decreases the spread of pediatric bone cancer.
The first study of Ewing's sarcoma that screened hundreds of genes based on how they affect cell growth has identified two potential anti-cancer drug targets.
SAN DIEGO, July 22 /PRNewswire/ -- MabVax Therapeutics Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that the first patients have been enrolled in a Phase II clinical trial aimed at assessing the efficacy and safety of its vaccine to prevent or delay the recurrence of sarcoma.
HIGH WYCOMBE, England, July 9, 2010 /PRNewswire/ -- - In a draft appraisal the National Institute for Health and Clinical Excellence (NICE) has refused to recommend the first treatment shown to improve survival in childhood bone cancer (osteosarcoma) in more than 20 years(1,2) - Data shows Mepact(R) (mifamurtide) reduces the risk of death by almost one third when added to standard chemotherapy treatment, compared with chemotherapy alone(3) - Using...
Kaposi's sarcoma-associated herpesvirus (KSHV) one of seven currently known human cancer virus, is also the eighth human herpesvirus. Kaposi's sarcoma, caused by the virus, is common in AIDS patients, primary effusion lymphoma, and some types of multicentric Castelman's disease. Moritz Kaposi discovered the blood vessel tumor, in 1872, which would eventually be names Kaposi's sarcoma. It was originally though that KS was of Jewish and Mediterranean origins until it was found to be common...
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).